Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment-A consensus report from the Pulmonary Council of the ISHLT.

[1]  G. Verleden,et al.  Chronic lung allograft dysfunction: Definition and update of restrictive allograft syndrome-A consensus report from the Pulmonary Council of the ISHLT. , 2019, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[2]  G. Verleden,et al.  Pirfenidone in restrictive allograft syndrome after lung transplantation: A case series , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  S. Keshavjee,et al.  Comprehensive outcomes after lung retransplantation: A single‐center review , 2018, Clinical transplantation.

[4]  T. Welte,et al.  Detection of chronic lung allograft dysfunction using ventilation‐weighted Fourier decomposition MRI , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  Marco Schiavon,et al.  Normothermic ex-vivo preservation with the portable Organ Care System Lung device for bilateral lung transplantation (INSPIRE): a randomised, open-label, non-inferiority, phase 3 study. , 2018, The Lancet. Respiratory medicine.

[6]  J. Nagendran,et al.  Baseline lung allograft dysfunction is associated with impaired survival after double-lung transplantation. , 2018, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[7]  S. Keshavjee,et al.  Upregulation of alveolar neutrophil enzymes and long pentraxin‐3 in human chronic lung allograft dysfunction subtypes , 2018, The Journal of thoracic and cardiovascular surgery.

[8]  G. Verleden,et al.  Montelukast for bronchiolitis obliterans syndrome after lung transplantation: A randomized controlled trial , 2018, PloS one.

[9]  C. Benden,et al.  Therapy options for chronic lung allograft dysfunction-bronchiolitis obliterans syndrome following first-line immunosuppressive strategies: A systematic review. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[10]  F. Wacker,et al.  CT at onset of chronic lung allograft dysfunction in lung transplant patients predicts development of the restrictive phenotype and survival. , 2017, European journal of radiology.

[11]  L. Lund,et al.  The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Lung And Heart-Lung Transplantation Report-2017; Focus Theme: Allograft ischemic time. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[12]  T. Welte,et al.  “White‐Out” After Lung Transplantation: A Multicenter Cohort Description of Late Acute Graft Failure , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  D. Landsittel,et al.  Long‐Term Follow‐up of a Randomized Controlled Trial Evaluating a Mobile Health Intervention for Self‐Management in Lung Transplant Recipients , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[14]  A. Glanville.  Physiology of chronic lung allograft dysfunction: back to the future? , 2017, European Respiratory Journal.

[15]  G. Verleden,et al.  High-dose vitamin D after lung transplantation: A randomized trial. , 2017, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[16]  J. Solé,et al.  BALF cytokines in different phenotypes of chronic lung allograft dysfunction in lung transplant patients , 2017, Clinical transplantation.

[17]  R. Herrmann,et al.  Mesenchymal Stromal Cell Therapy for Chronic Lung Allograft Dysfunction: Results of a First‐in‐Man Study , 2017, Stem cells translational medicine.

[18]  T. Welte,et al.  Comparative analysis of morphological and molecular motifs in bronchiolitis obliterans and alveolar fibroelastosis after lung and stem cell transplantation , 2016, The journal of pathology. Clinical research.

[19]  G. Verleden,et al.  Predictors of survival in restrictive chronic lung allograft dysfunction after lung transplantation. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[20]  J. Gottlieb,et al.  Nintedanib in restrictive chronic lung allograft dysfunction after lung transplantation. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[21]  G. Verleden,et al.  Antibody-mediated rejection of the lung: A consensus report of the International Society for Heart and Lung Transplantation. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[22]  B. Bettencourt,et al.  ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[23]  G. Verleden,et al.  Prophylactic Azithromycin Therapy After Lung Transplantation: Post hoc Analysis of a Randomized Controlled Trial , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[24]  S. Verleden,et al.  Impact of CLAD Phenotype on Survival After Lung Retransplantation: A Multicenter Study , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[25]  G. Yung,et al.  Lung transplantation and extracorporeal photopheresis: The answer to bronchiolitis obliterans? , 2015, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[26]  S. Keshavjee,et al.  Functional outcomes and quality of life after normothermic ex vivo lung perfusion lung transplantation. , 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[27]  G. Verleden,et al.  Differential Cytokine, Chemokine and Growth Factor Expression in Phenotypes of Chronic Lung Allograft Dysfunction , 2015, Transplantation.

[28]  J. Lordan,et al.  A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation , 2012, Thorax.

[29]  A. Kapila,et al.  Reliability of diagnostic criteria for bronchiolitis obliterans syndrome after lung transplantation: a survey. , 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[30]  P. Corris,et al.  Three-year results of an investigator-driven multicenter, international, randomized open-label de novo trial to prevent BOS after lung transplantation. , 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[31]  A. Glanville.  CLAD: Does the Emperor Have New Clothes? , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[32]  G. Verleden,et al.  An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome , 2014, European Respiratory Journal.

[33]  G. Lang,et al.  Alemtuzumab in Lung Transplantation: An Open‐Label, Randomized, Prospective Single Center Study , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[34]  M. Sato,et al.  Distinct Expression Patterns of Alveolar “Alarmins” in Subtypes of Chronic Lung Allograft Dysfunction , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[35]  G. Verleden,et al.  A new classification system for chronic lung allograft dysfunction. , 2014, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[36]  C. de Wall,et al.  Home spirometry as early detector of azithromycin refractory bronchiolitis obliterans syndrome in lung transplant recipients. , 2014, Respiratory medicine.

[37]  G. Verleden,et al.  Elevated Bronchoalveolar Lavage Eosinophilia Correlates With Poor Outcome After Lung Transplantation , 2014, Transplantation.

[38]  L. Snyder,et al.  Impact of forced vital capacity loss on survival after the onset of chronic lung allograft dysfunction. , 2014, American journal of respiratory and critical care medicine.

[39]  G. Verleden,et al.  Pirfenidone: A Potential New Therapy for Restrictive Allograft Syndrome? , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[40]  G. Opelz,et al.  The collaborative transplant study registry. , 2013, Transplantation reviews.

[41]  T. Welte,et al.  Phenotyping Established Chronic Lung Allograft Dysfunction Predicts Extracorporeal Photopheresis Response in Lung Transplant Patients , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[42]  N. Jewell,et al.  Association of large-airway lymphocytic bronchitis with bronchiolitis obliterans syndrome. , 2013, American journal of respiratory and critical care medicine.

[43]  S. Keshavjee,et al.  Restrictive allograft syndrome post lung transplantation is characterized by pleuroparenchymal fibroelastosis , 2013, Modern Pathology.

[44]  S. Keshavjee,et al.  Progression pattern of restrictive allograft syndrome after lung transplantation. , 2013, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[45]  C. Benden,et al.  Impact of Sinus Surgery on Pseudomonal Airway Colonization, Bronchiolitis Obliterans Syndrome and Survival in Cystic Fibrosis Lung Transplant Recipients , 2012, Respiration.

[46]  H. Reichenspurner,et al.  Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: results of a prospective, randomized international trial in lung transplantation. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[47]  J. Golden,et al.  172 Cyclosporine Inhalation Solution Does Not Improve Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplant: Results from the CYCLIST Trial , 2012 .

[48]  S. Keshavjee,et al.  Revisiting the pathologic finding of diffuse alveolar damage after lung transplantation. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[49]  J. Gaughan,et al.  Total lung capacity by plethysmography and high-resolution computed tomography in COPD , 2012, International journal of chronic obstructive pulmonary disease.

[50]  G. Verleden,et al.  Survival Determinants in Lung Transplant Patients With Chronic Allograft Dysfunction , 2011, Transplantation.

[51]  T. Welte,et al.  Graft-Protective Effects of the HMG-CoA Reductase Inhibitor Pravastatin After Lung Transplantation— A Propensity Score Analysis With 23 Years of Follow-Up , 2011, Transplantation.

[52]  G. Verleden,et al.  Montelukast for bronchiolitis obliterans syndrome after lung transplantation: a pilot study , 2011, Transplant international : official journal of the European Society for Organ Transplantation.

[53]  S. Keshavjee,et al.  Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[54]  M. Iversen,et al.  Treatment of intractable interstitial lung injury with alemtuzumab after lung transplantation. , 2011, Transplantation proceedings.

[55]  G. Verleden,et al.  Bile Acids Aspiration Reduces Survival in Lung Transplant Recipients with BOS Despite Azithromycin , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[56]  G. Patterson,et al.  Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[57]  G. Verleden,et al.  A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation , 2010, European Respiratory Journal.

[58]  G. Patterson,et al.  Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[59]  A. Glanville,et al.  Bronchoscopic Monitoring after Lung Transplantation , 2010, Seminars in respiratory and critical care medicine.

[60]  G. Verleden,et al.  Efficacy of total lymphoid irradiation in azithromycin nonresponsive chronic allograft rejection after lung transplantation. , 2009, Transplantation proceedings.

[61]  J. Behr,et al.  Prognostic value of bronchoalveolar lavage neutrophilia in stable lung transplant recipients. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[62]  T. Welte,et al.  Long-Term Azithromycin for Bronchiolitis Obliterans Syndrome After Lung Transplantation , 2008, Transplantation.

[63]  G. Verleden,et al.  Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. , 2006, American journal of respiratory and critical care medicine.

[64]  B. Griffith,et al.  A randomized trial of inhaled cyclosporine in lung-transplant recipients. , 2006, The New England journal of medicine.

[65]  S. Keshavjee,et al.  Upper lobe fibrosis: a novel manifestation of chronic allograft dysfunction in lung transplantation. , 2005, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[66]  J. Hankinson,et al.  Standardisation of spirometry , 2005, European Respiratory Journal.

[67]  P. Corris,et al.  The Safety and Efficacy of Total Lymphoid Irradiation in Progressive Bronchiolitis Obliterans Syndrome After Lung Transplantation , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[68]  J. Lordan,et al.  Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. , 2005, American journal of respiratory and critical care medicine.

[69]  G. Verleden,et al.  AZITHROMYCIN THERAPY FOR PATIENTS WITH BRONCHIOLITIS OBLITERANS SYNDROME AFTER LUNG TRANSPLANTATION , 2004, Transplantation.

[70]  J. Orens,et al.  Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. , 2003, American journal of respiratory and critical care medicine.

[71]  K. McCurry,et al.  Statin use is associated with improved function and survival of lung allografts. , 2003, American journal of respiratory and critical care medicine.

[72]  Marshall Hertz,et al.  Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[73]  D. Howell,et al.  Gastroesophageal reflux as a reversible cause of allograft dysfunction after lung transplantation. , 2000, Chest.

[74]  G. Patterson,et al.  A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. , 1993, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.